$4.81
+0.45 (+10.32%)
Open$4.69
Previous Close$4.36
Day High$5.59
Day Low$4.66
52W High$7.19
52W Low$3.22
Volume—
Avg Volume231.6K
Market Cap134.19M
P/E Ratio—
EPS$-1.75
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+619.5% upside
Current
$4.81
$4.81
Target
$34.61
$34.61
$23.82
$34.61 avg
$34.97
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 71.70M | 56.17M | 25.19M |
| Net Income | -48,650,230 | -34,298,297 | -2,467,246 |
| Profit Margin | -67.9% | -64.5% | -9.8% |
| EBITDA | -41,279,744 | -30,718,907 | -4,050,890 |
| Free Cash Flow | — | — | -1,532,934 |
| Rev Growth | +27.7% | +27.7% | +20.8% |
| Debt/Equity | 9.39 | 9.39 | 0.40 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |